Last reviewed · How we verify

NCT05520398: ERP in Silico

Neural Mechanisms of Obsessive-compulsive Disorder (OCD) Treatment Failure

Recruiting now Last updated 19 December 2024
What this trial tests

trial in Obsessive-Compulsive Disorder in 90 participants. Currently enrolling.

Timeline
10 November 2021
Primary endpoint
31 December 2025
31 December 2025

Quick facts

Lead sponsorUniversity College, London
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment90
Start date10 November 2021
Primary completion31 December 2025
Estimated completion31 December 2025
Sites1 location across United Kingdom

Conditions studied

Sponsor

University College, London

Who can join

Adults 18 to 55, any sex, with Obsessive-Compulsive Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to understand why patients with obsessive-compulsive disorder (OCD) fail in therapy. To understand the neural mechanisms involved in exposure therapy that support success and clinical improvement in order to improve therapy outcomes for OCD patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Obsessive-Compulsive Disorder

Currently open trials in the same condition.

Other University College, London trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05520398.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing